Scott D. Myers Appointed Oncothyreon's CEO
This article was originally published in Scrip
Oncothyreon Inc. has appointed Scott D. Myers president and CEO; he most recently held the same positions at Aerocrine AB (acquired by Circassia Pharmaceuticals). Myers was previously an independent director for Orexo AB and is currently an industry advisor to EQT, a Scandinavian investment fund.
Register for our free email digests: